NASDAQ · UPB
Upstream Bio, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for UPB: Nov 4, 2026
Upstream Bio, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.67. The reported EPS for the same quarter last year was $-0.63.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.67 | $-0.52 | $-0.82 | 5 |
| Dec 2026 | $-0.66 | $-0.42 | $-0.84 | 5 |
| Mar 2027 | $-0.68 | $-0.60 | $-0.84 | 3 |
| Jun 2027 | $-0.69 | $-0.60 | $-0.84 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · BNK Invest · Fintel- RTTNews · Aug 13, 5:21 AM EDTUpstream Posts Narrower Loss In Q2; Expects Phase 2 Readouts For Verekitug In H2 2027(RTTNews) – Upstream Bio, Inc. (UPB) a clinical-stage biotech company, released second quarter results demonstrating a narrower loss due to decreased operating costs.
- Zacks · Aug 11, 8:35 AM EDTUpstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue EstimatesUpstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +6.41% and +15.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 14, 12:00 PM EDTUpstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- RTTNews · Jun 15, 3:39 AM EDTUpstream Bio Presents Clinically Meaningful Improvements In Phase 2 VIBRANT Trial On Verekitug(RTTNews) – Upstream Bio Inc. (UPB) reported new responder analyses from its Phase 2 VIBRANT trial showing that a significant majority of patients with chronic rhinosinusitis with nasal polyps experienced clinically meaningful improvements when treated with Verekitug. The data we
- Zacks · May 13, 8:20 AM EDTUpstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue EstimatesUpstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +5.96% and +102.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Apr 30, 9:25 AM EDTAlnylam Pharmaceuticals (ALNY) Tops Q1 Earnings and Revenue EstimatesAlnylam (ALNY) delivered earnings and revenue surprises of +39.00% and +2.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Feb 13, 10:39 AM ESTWeekly Buzz:FDA Okays NVCR's Cancer Device; RGNX Gets CRL;ONCO To Buy XBOT; PHIO's PH-762 Sets Pace(RTTNews) – The biotech sector witnessed a few regulatory setbacks, Type B meetings that went well, noteworthy approvals, acquisitions, and clinical trials that met primary endpoints across key therapeutic areas, including achondroplasia, asthma, skin cancers, and actinic keratos
- RTTNews · Feb 11, 3:56 AM ESTUpstream Bio To Present Phase 2 VALIANT Trial Results In Severe Asthma, Today(RTTNews) – Upstream Bio (UPB) will host a webcast today to present top-line results from its Phase 2 VALIANT trial evaluating Verekitug, a first-in-class antagonist of the thymic stromal lymphopoietin (TSLP) receptor, in patients with severe asthma.
- BNK Invest · Jan 28, 3:20 PM ESTNotable Wednesday Option Activity: AAOI, PNTG, UPBLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Applied Optoelectronics Inc (Symbol: AAOI), where a total volume of 30,236 contracts has been traded thus far today, a contract volume which is representative of
- Fintel · Dec 18, 7:03 AM ESTMizuho Initiates Coverage of Upstream Bio (UPB) with Outperform RecommendationFintel reports that on December 18, 2025, Mizuho initiated coverage of Upstream Bio (NasdaqGS:UPB) with a Outperform recommendation. Analyst Price Forecast Suggests 80.02% Upside
- Fintel · Dec 2, 7:05 PM ESTLifeSci Capital Initiates Coverage of Upstream Bio (UPB) with Outperform RecommendationFintel reports that on December 2, 2025, LifeSci Capital initiated coverage of Upstream Bio (NasdaqGS:UPB) with a Outperform recommendation. Analyst Price Forecast Suggests 114.70% Upside
- BNK Invest · Nov 21, 11:47 AM ESTCommit To Buy Upstream Bio At $20, Earn 80.2% Annualized Using OptionsInvestors eyeing a purchase of Upstream Bio Inc (Symbol: UPB) shares, but cautious about paying the going market price of $25.60/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Upstream Bio, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.